Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Size, Share,...

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Size, Share, and Growth Forecast 2031

Posted 2025-03-05 19:02:04

"The Chimeric Antigen Receptor (CAR)-T Cell Therapy Market sector is undergoing rapid transformation, with significant growth and innovations expected by 2031. In-depth market research offers a thorough analysis of market size, share, and emerging trends, providing essential insights into its expansion potential. The report explores market segmentation and definitions, emphasizing key components and growth drivers. Through the use of SWOT and PESTEL analyses, it evaluates the sector’s strengths, weaknesses, opportunities, and threats, while considering political, economic, social, technological, environmental, and legal influences. Expert evaluations of competitor strategies and recent developments shed light on geographical trends and forecast the market’s future direction, creating a solid framework for strategic planning and investment decisions.

Get a Sample PDF of Report - https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-car-t-cell-therapy-market

Which are the top companies operating in the Chimeric Antigen Receptor (CAR)-T Cell Therapy Market?

The report profiles noticeable organizations working in the water purifier showcase and the triumphant methodologies received by them. It likewise reveals insights about the share held by each organization and their contribution to the market's extension. This Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market report provides the information of the Top Companies in Chimeric Antigen Receptor (CAR)-T Cell Therapy Market in the market their business strategy, financial situation etc.

Autolus Therapeutics (U.K), CARsgen Therapeutics Co.Ltd. (U.K), Juno Therapeutics, Inc.(U.S), Sorrento Therapeutics, Inc. (U.S)., bluebird bio, Inc. (U.S), CELGENE CORPORATION (U.S), Eureka Therapeutics Inc. (U.S), Avacta Life Sciences Ltd. (U.K), Calyxt Inc. (France), Celyad Oncology SA (Belgium), Fortress Biotech, Inc (U.S.)., IMMUNE THERAPEUTICS, INC (U.S.), Gilead Sciences, Inc. (U.S.), Novartis AG (Switzerland), Alaunos Therapeutics, Inc (U.S.)., Poseida Therapeutics, Inc. (U.S.)

Report Scope and Market Segmentation

Which are the driving factors of the Chimeric Antigen Receptor (CAR)-T Cell Therapy Market?

The driving factors of the Chimeric Antigen Receptor (CAR)-T Cell Therapy Market are multifaceted and crucial for its growth and development. Technological advancements play a significant role by enhancing product efficiency, reducing costs, and introducing innovative features that cater to evolving consumer demands. Rising consumer interest and demand for keyword-related products and services further fuel market expansion. Favorable economic conditions, including increased disposable incomes, enable higher consumer spending, which benefits the market. Supportive regulatory environments, with policies that provide incentives and subsidies, also encourage growth, while globalization opens new opportunities by expanding market reach and international trade.

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market - Competitive and Segmentation Analysis:

**Segments**

- By Target Antigen (CD19, CD22, BCMA, Others)
- By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others)
- By End-User (Hospitals, Clinics, Research Institutes)

Chimeric antigen receptor (CAR) T-cell therapy has been gaining significant traction in the global market in recent years due to its promising results in treating various types of cancer. The market size is expected to witness robust growth by the year 2031, driven by the increasing prevalence of cancer worldwide and the growing adoption of personalized medicine.

The market segments based on target antigen include CD19, CD22, BCMA, and others. Among these, the CD19 segment is expected to dominate the market during the forecast period owing to its high expression in various hematologic malignancies. In terms of applications, CAR-T cell therapy is widely used in treating acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, and others. The increasing incidence of these cancer types is anticipated to drive the growth of the market.

The end-users of CAR-T cell therapy include hospitals, clinics, and research institutes. Hospitals are expected to account for the largest share in the market as they are the primary healthcare settings where cancer patients undergo treatment. The rising investments in research and development activities by various research institutes are also expected to contribute to the market growth.

**Market Players**

- Novartis AG
- Gilead Sciences, Inc.
- Celgene Corporation
- Bluebird Bio, Inc.
- Juno Therapeutics
- Legend Biotech Corporation
- CARsgen Therapeutics
- Sorrento Therapeutics
- Atara Biotherapeutics
- AbbVie Inc.

The global CAR-T cellThe global chimeric antigen receptor (CAR) T-cell therapy market is witnessing significant growth, driven by factors such as the increasing incidence of cancer, advancements in personalized medicine, and the promising outcomes of CAR-T cell therapies in treating various cancer types. The market segmentation based on the target antigen, application, and end-user provides a comprehensive understanding of the dynamics within this market.

Different target antigens such as CD19, CD22, BCMA, and others play a crucial role in determining the efficacy of CAR-T cell therapy. Among these, CD19 stands out as a dominant segment due to its high expression in hematologic malignancies, making it a preferred target for therapy development. The specificity and effectiveness of targeting these antigens contribute to the success of CAR-T cell therapies in treating cancers.

In terms of applications, CAR-T cell therapy is being increasingly utilized across a spectrum of cancer types including acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, and more. The versatility of CAR-T cell therapy in addressing a wide range of cancers underscores its potential as a transformative treatment option in the field of oncology. The strong clinical outcomes observed in these diverse applications are propelling market growth and adoption among healthcare providers and patients.

End-users in the CAR-T cell therapy market primarily consist of hospitals, clinics, and research institutes. Hospitals, being the frontline healthcare providers for cancer treatment, are expected to hold a significant market share. The infrastructure, expertise, and resources available in hospital settings make them well-equipped to administer and manage CAR-T cell therapy for patients. Additionally, research institutes play a vital role in advancing CAR-T cell therapy through ongoing research and development efforts, which are essential for driving innovation and improving treatment outcomes in the long run.

The market players in the CAR-T cell therapy landscape include industry leaders such as Novartis AG, Gilead Sciences, Inc., Celgene Corporation, Bluebird Bio, Inc**Market Players**
- Autolus Therapeutics (U.K)
- CARsgen Therapeutics Co.Ltd. (U.K)
- Juno Therapeutics, Inc. (U.S)
- Sorrento Therapeutics, Inc. (U.S)
- bluebird bio, Inc. (U.S)
- CELGENE CORPORATION (U.S)
- Eureka Therapeutics Inc. (U.S)
- Avacta Life Sciences Ltd. (U.K)
- Calyxt Inc. (France)
- Celyad Oncology SA (Belgium)
- Fortress Biotech, Inc (U.S)
- IMMUNE THERAPEUTICS, INC (U.S)
- Gilead Sciences, Inc. (U.S)
- Novartis AG (Switzerland)
- Alaunos Therapeutics, Inc (U.S)
- Poseida Therapeutics, Inc. (U.S)

The global chimeric antigen receptor (CAR) T-cell therapy market is experiencing a significant surge in growth, fueled by a combination of factors such as the rising incidence of cancer, advancements in personalized medicine, and the promising outcomes achieved through CAR-T cell therapies in the treatment of various cancer types. The division of the market into segments based on the target antigen, application, and end-user provides valuable insights into the intricate nature of this evolving market.

The selection of target antigens such as CD19, CD22, BCMA, and others plays a pivotal role in determining the efficacy

North America, particularly the United States, will continue to exert significant influence that cannot be overlooked. Any shifts in the United States could impact the development trajectory of the Chimeric Antigen Receptor (CAR)-T Cell Therapy Market. The North American market is poised for substantial growth over the forecast period. The region benefits from widespread adoption of advanced technologies and the presence of major industry players, creating abundant growth opportunities.

Similarly, Europe plays a crucial role in the global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market, expected to exhibit impressive growth in CAGR from 2024 to 2031.

Explore Further Details about This Research Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Report https://www.databridgemarketresearch.com/reports/global-car-t-cell-therapy-market

Key Benefits for Industry Participants and Stakeholders: –

Industry drivers, trends, restraints, and opportunities are covered in the study.
Neutral perspective on the Chimeric Antigen Receptor (CAR)-T Cell Therapy Market scenario
Recent industry growth and new developments
Competitive landscape and strategies of key companies
The Historical, current, and estimated Chimeric Antigen Receptor (CAR)-T Cell Therapy Market size in terms of value and size
In-depth, comprehensive analysis and forecasting of the Chimeric Antigen Receptor (CAR)-T Cell Therapy Market

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historical data and forecast (2024-2031) of the following regions are covered in Chapters

The countries covered in the Chimeric Antigen Receptor (CAR)-T Cell Therapy Market report are U.S., Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, and Rest of the Middle East and Africa

Detailed TOC of Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Insights and Forecast to 2031

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Landscape

Part 05: Pipeline Analysis

Part 06: Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Sizing

Part 07: Five Forces Analysis

Part 08: Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers And Challenges

Part 13: Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Browse More Reports:

Data Bridge Market Research:

Today's trends are a great way to predict future events!

Data Bridge Market Research is a market research and consulting company that stands out for its innovative and distinctive approach, as well as its unmatched resilience and integrated methods. We are dedicated to identifying the best market opportunities, and providing insightful information that will help your business thrive in the marketplace. Data Bridge offers tailored solutions to complex business challenges. This facilitates a smooth decision-making process. Data Bridge was founded in Pune in 2015. It is the product of deep wisdom and experience.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC: +653 1251 1240

Email:- corporatesales@databridgemarketresearch.com
"